Last Updated: 06 Nov 2024
Executive Summary
Mangoceuticals, Inc. (MGRX) is a small-cap healthcare company operating in the men's wellness market. Despite a strong revenue growth in the latest quarter, the company faces significant profitability challenges, with negative EBITDA and EPS. The stock is currently trading at a discount to its book value, but its high Price-to-Sales ratio and negative ROA and ROE raise concerns about its valuation. The lack of analyst coverage and low trading volume limit the availability of external insights.
Company Overview
Mangoceuticals, Inc. develops and markets men's wellness products and services through a telemedicine platform. The company's products include supplements, devices, and lifestyle coaching programs. Mangoceuticals is headquartered in Dallas, Texas, and has a market capitalization of approximately $5.99 million.
Fundamental Analysis
Revenue: Mangoceuticals reported revenue of $866,790 for the trailing twelve months (TTM), representing a 15.5% increase year-over-year.
Profitability: The company's profitability metrics are weak, with a TTM EBITDA of -$8,505,153 and a TTM EPS of -$6.45.
Valuation: MGRX is currently trading at a Price-to-Sales ratio of 6.91, which is higher than the industry average. Its Price-to-Book ratio of 0.431 suggests that the stock is trading at a discount to its book value.
Financial Health: Mangoceuticals has a negative Return on Assets (ROA) of -0.575% and a negative Return on Equity (ROE) of -1.084%, indicating that the company is not generating sufficient returns on its investments.
Technical Analysis
Trend: The stock is currently trading below its 50-day and 200-day moving averages, indicating a bearish trend.
Support and Resistance: The stock has support at $2.10, its 52-week low, and resistance at $3.309, its 50-day moving average.
Volume: Trading volume has been low in recent months, which limits the reliability of technical indicators.
Short Term Outlook
In the short term, MGRX faces challenges due to its negative profitability and lack of analyst coverage. The stock's technical indicators suggest a bearish trend, with the price below key moving averages. A break below $2.10 could lead to further downside.
Long Term Outlook
The long-term outlook for MGRX depends on the company's ability to improve its profitability and generate sustainable revenue growth. The men's wellness market is competitive, and Mangoceuticals will need to differentiate itself and execute its business plan effectively to succeed.
Analyst Recommendations
No analyst recommendations are available for MGRX.
